Quality – Importance of Making Quality Products

Your Objectives:

At the end of the lesson, you should be able to accurately assess the impact of a lack of quality in the biotech industry and thereby understand the importance of quality assurance systems and the key role of documentation.

But first, a case study from January 1999 (Brussels BELG / Melsungen DE):

When Health Minister Marcel Colla announced that two preterm infants had died in a Belgian hospital after being poisoned due to an incorrectly labelled infusion solution there was much trepidation. Authorities swiftly informed clinics across Europe. The German pharmaceutical

company B. Braun Melsungen Inc., which had supplied the

reacted in dismay to the incident calling back their product.

In the meantime, the Belgian judiciary launched a criminal investigation into B. Braun and found

that as many as 135,000 wrongly	ampoules had been put into
circulation in September 1997 in Belgium, Germany,	Luxembourg and Slovakia. They cited
error in the packaging of the	ne product as the probable cause of the
fatal accident. The babies had been	with the supposed sugar

solution directly; the ampoules contained **potassium chloride*** instead of a **glucose solution****.

Potassium chloride is sometimes administered intravenously in adults for regulating the iron

content in the

A preterm, weighing less than one kilogram at birth, died. In the same week, another girl born seven weeks prematurely. According to spokesperson Christine Verheyden (University Clinic in Leuven), under normal procedure, "[they] would have had a good chance of survival." Instead, they died of cardiac arrest. The doctors treating her were initially not suspicious, however. It goes without saying, "for a baby, the dose that was in the vial was far too high." In the hospital,

three other incorrectly identified ampoules containing the toxic

were found in a large package. The vials came from a package that B. Braun had delivered to the clinic. A company spokesman in Melsungen said he "[had] no reason to believe" that the deaths in Belgium were due to misconduct by medical personnel. The company said that the most likely cause of the tragic incident was "human error in the assembly area of production." A technical error in the production itself can be excluded.

The life sciences			is seeing inc	reasing demand	ls and the	refore it
requires absolute	control over			quality. Qualit	y costs***	' already
make up close	e to 30 per	rcent of			costs	in the
	indus	stry, making	it one of th	ne biggest sper	nders in tl	nis area.
(Investopedia, 201	L8-2019) The imp	oact of		issue	s on total o	costs has
doubled over the	past five years. Th	herefore, the			of quality	systems
is essential to redu	uce costs and ens	ure greater s	ystem			
The biggest challe	enge for a quality	y system is t	o ensure pati	ents'		
while keeping in	compliance with	applicable	regulatory req	quirements. Co	mpanies a	re faced
with the challen	ge of integratin	ng into the	quality			systems
regulatory require	ments under the	e legislature a	as well as thei	r own complian	ce guidelir	nes, with
the aim of reduc	ing the number	of		at all lo	evels of tl	ne value
stream chain.						
Both manufacturi	ng processes and	d quality syst	ems themsel	ves have chang	ed constar	ntly over

the past 25 years due to frequent changes to the regulatory requirements and the expansion of

sales to other markets with varying requirements. As a result,

quality systems in the pharmaceutical industry must be more and more effectively designed to

ensure efficient risk at all levels of pharmaceutical manufacturing.

On average, of the current processes, 75 percent of the deviations

(one or two deviations per batch) are due to human error. Most companies currently have a right-first-time rate at operator level of close to nil in connection with the batch record and the release procedure. The consequences are increased scrap, more deviations, fewer batch releases, delivery bottlenecks, etc.

The complexity and intricacies involved in these "regulatory" documents have

for quality assurance within any pharmaceutical company. The

operators regard documentation as a evil, though it does not

allow autonomy. Meanwhile, proper training and adequate standardization of working methods is very difficult to manage. Having said that, a predominantly oral

will likely be more prone to and

inconsistent behaviours, , human error or to batches that cannot

be released. Moreover, maintaining the document system is becoming more and more expensive: Declining efficiency despite great efforts at following documentation systems, and continuous improvement of R&D, is a burden. Finally, some existing errors remain

and resolved, which can result in performance losses (fewer batch

releases, further deviations, human error, etc.).

* **Potassium chloride** is used to prevent or to treat hypokalemia, or low blood levels of potassium.

**** Antenatal corticosteroids** (ACS)—is also used for patients with diabetes

***** Quality costs**: preventing, detecting, and remediating product issues related to quality.

Aufgabe Lückentext:

Folgende Wörter bitte in den Lückentext einfüllen. Jedes Wort kommt einmal vor. Bitte Gross- und Kleinbuchstaben beachten.

ampoules, assurance, blood, consequences, culture, deviations, human, efficiency, errors, international, injected, industry, labelled, management, manufacturing, necessary, optimization, product, pharmaceutical, quality, solution, safety, total, uncoordinated, undetected